733 results about "Lacceroic acid" patented technology

This invention is directed to the field of medical implants, and more specifically to biodegradable injectable implants and their methods of manufacture and use. The injectable implants disclosed herein comprise glycolic acid and bio-compatible/bio-absorbable polymeric particles containing a polymer of lactic acid. The particles are small enough to be injected through a needle but large enough to avoid engulfment by macrophages. The injectables of this invention may be in a pre-activated solid form or an activated form (e.g., injectable suspension or emulsion).

Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-δ-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen).

wherein X represents a halogen or hydrogen.

The present invention relates to a testing system for assessing hypoxia induced cellular damage in a mammal including human, comprising a disposable device having a sample inlet and a collection chamber separated by a separation device wherein the collection chamber is connected to at least two, a first and a second, visible detection compartments, whereof at least one is arranged with chemical means for direct visual detection, said first detection compartment being arranged to determine whether level of hemoglobin (Hb) in a sample of body fluid taken from said mammal exceeds a predetermined threshold value, and said second detection compartment being arranged to evaluate level of total amount of lactate dehydrogenase (LDH) in said sample.

The invention discloses slow-release microspheres coated with rivastigmine tartrate/rivastigmine for PLGA/PLA injection and a preparation method thereof. The slow-release microspheres mainly comprise rivastigmine tartrate/rivastigmine and PLGA and PLA serving as biodegradable polymer medicinal materials, and can be prepared by adopting a W1/O/W2 composite emulsified solvent volatilization method, an O/W emulsified solvent volatilization method, an O1/O2 emulsion drying method and a spray drying method. The grain diameter of the microspheres is less than 100 microns. The slow-release microspheres have high medicament loading amount, have no obvious burst release effect, can be continuously released for one week, one mouth or three mouths, are used for treating senile diseases such as Alzheimer's disease, Parkinson disease and the like, and can prolong the acting time of the medicament, reduce the application times and greatly improve the administration compliance of patients.

The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

The invention relates to a neutral blockage removing agent composition used for an oil recovery formation in an oilfield. The neutral blockage removing agent composition is prepared from the following raw materials in parts by weight: 30-36 parts of disodium polyepoxysuccinicate, 18-25 parts of sodium gluconate, 2-3 parts of polyethylene glycol, 2-4 parts of triethanolamine, 9-12 parts of ethyl lactate, 7-10 parts of fatty alcohol polyoxyethylene ether sodium sulfate, 8-12 parts of amino acid sodium, 10-15 parts of activated attapulgite, 0.1-0.2 part of vanadium pentoxide, 5-7 parts of lipase, 5-8 parts of sorbitan fatty acid ester, 15-18 parts of P-hydroxy sodium sulfonate, 3-7 parts of tert-butyl hydroperoxide and 0.1-0.3 part of diethylene glycol monolaurate. The neutral blockage removing agent composition has high blockage removing speed, is neutral, is free of corrosion and can quickly dissolve material scales, asphalt sediment scales, carbonate scales, silicate scales and the like generated by an ASP flooding system; waste liquid for blockage removal can be degraded and does not need to be discharged onto the ground to be subjected to sewage treatment, the formation in the oilfield is cleaned to remove the blockage, no corrosion, dead angle, precipitation or secondary well blockage is generated, and the blockage removal time does not exceed 24 hours.

The invention relates to a synthesis technique of tenofovir, and relates to the field of medicinal chemistry. Using natural (R)-lactate as the starting material, chiral R-1,2-propanediol is obtained through reduction, and then reacted with diethyl carbonate under the action of alkali to obtain the key reaction intermediate R-propylene carbonate ester. Use adenine and R-propylene carbonate to prepare R-9-(2-hydroxypropyl)adenine; Gained R-9-(2-hydroxypropyl)adenine and diethyl p-toluenesulfonyloxyphosphate Under the catalysis of magnesium tert-butoxide, the condensation reaction is carried out to obtain R-9[(diethylphosphorylmethoxy)propyl]purine; the obtained R-9[2-(diethylphosphorylmethoxy) Propyl]purine is hydrolyzed to obtain Tenofovir. The process has short reaction steps, short required reaction time, high quality yield and good product quality, and is suitable for industrialized production.

An absorbable internal fixing material for bone fracture is prepared from polylactic acid (50-90 wt.%), tricalcium phosphate (1-40 wt.%) and hydroxylapatitie (1-40 wt.%) through mixing then and then hot die pressing at 80-1230 deg.C and under 0.11-25 MPa or hot extruding at 80-230 deg.c. The granulality of hydroxylapatite and tricalcium phosphate is less than 100 microns. Its advantages are high strength, high strength, high X-ray visualization and high biocompatibility.

The invention relates to a neutral blockage removing agent composition used for a mechanical recovery well in an oilfield. The neutral blockage removing agent composition is prepared from the following components in parts by weight: 16-20 parts of polyepoxysuccinic acid amine, 7-12 parts of hydroxyethylidene dipllosphate sodium, 21-25 parts of divinyl pentaacetic acid amine, 20-25 parts of hydroxyl ammonium acetate, 12-16 parts of activated attapulgite, 21-25 parts of ammonium persulfate, 9-12 parts ofdicyclohexyl sulfobutanedioate sodium, 7-9 parts of butyl lactate, 0.2-0.3 part of vanadium pentoxide, 5-8 parts of straight chain sodium dodecylbenzenesulfonate, 10-14 parts of nitrilotriacetic acid sodium salt, 4-7 parts of urotropin and 0.1-0.3 part of glycerin fatty acid ester. The neutral blockage removing agent composition is suitable for scale removal and blockage removal of an oil pumping unit well and a screw pump well, can effectively control the reaction speed of the blockage removing agent and the scale of the oil pumping unit well and the scaled screw pump well, and prevent the falling-off of big scale residues to result in the secondary blockage of the mechanical recovery well and an oil recovery pump thereof, has high blockage removal speed, is neutral and is free of corrosion; the waste liquid for blockage removal does not need to be discharged onto the ground to be subjected to sewage treatment, the blockage removal time does not exceed 24 hours, and the effect of safe and corrosion-free blockage removal is achieved.

Provided are hair processing agents capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair processing agents in which an unpleasant odor is masked. Hair processing agents contain at least one compound represented by the formula (2). Hair processing agents contain a compound of the formula (2) and at least one compound (ii) selected from thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, salts thereof and ester derivatives thereof. Hair processing agents contain a compound of the formula (2), a surfactant and water, and are emulsified. Hair processing agents contain a compound of the formula (2) and a specific perfume. wherein X is a structure selected from —O—, —S—, —NH— and —NR¹—; R¹ is an alkyl group of 1 to 6 carbon atoms; Y is an oxygen atom or a sulfur atom; in the formula (1), Z is a divalent organic residue having at least one mercapto group; in the formula (2), R is a divalent organic residue optionally having a mercapto group; and R² is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms.

A corneal storage solution which maintains cell density and cell viability of corneas stored in vitro for a period of greater than four days up to about two weeks is provided. The solution contains a buffered, balanced, nutrient and electrolyte aqueous solution, at least one colloidal osmotic agent, a phenolic antioxidant compound, a non-lactate-generating substrate, a thiol-containing compound, insulin, and at least one antibiotic. A method for in vitro storage and preservation of the viability of human corneal endothelial cells for subsequent use includes the steps of removing a cornea from an eye globe and placing the cornea in the above corneal storage solution.

A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.

The invention relates to the field of biotechnology in the pharmaceutical industry, and discloses the preparation of an immobilized whole-cell catalyst and its application in the synthesis of a Puley intermediate (R)-2-hydroxy-4-phenyl-butyric acid. The recombinant cells containing the D-type lactate dehydrogenase gene and the formate dehydrogenase gene are established and fixed to prepare the immobilized whole cell catalyst. Using this catalyst to synthesize the intermediate (R)-2-hydroxy-4-phenyl-butyric acid of lisinopril, the reaction conditions are mild, the action is specific, and there are no by-products. It is used in medicine and food industries. value.

Lactic acid, lactic acid derivatives, or mixtures thereof are dehydrated using a catalyst and process to produce bio-acrylic acid, acrylic acid derivatives, or mixtures thereof. A method to produce the catalyst is also provided.

The invention discloses cool peppermint essence for a menthol cigarette ice blast and a preparation method and application of the essence. The cool peppermint essence is prepared from, by mass, 1%-8% of menthol, 1%-10% of menthyl lactate, 1%-5% of menthyl acetate, 0.2%-0.5% of cooling agent and the balance grease solvent. According to the cool peppermint essence for the menthol cigarette ice blast and the preparation method and application of the essence, when the ice blast is pinched broken, natural peppermint fragrance and cooling feeling can be brought to a cigarette without herb flavor and irritation of menthol, the ice blast can be well integrated with the cigarette, the cigarette smoking comfort is effectively improved, and the smoking quality of the cigarette is improved.

The invention relates to a neutral blocking remover composition for oilfield oil extraction, which is prepared from the following components in parts by weight: 30-35 parts of acrylic acid-methyl acrylate copolymer, 44-50 parts of diethylene triamine pentaacetic acid, 30-35 parts of sodium polyepoxysuccinate, 30-35 parts of amine malate, 10-14 parts of sodium alkyl sulfonate, 5-8 parts of amine hydroxy ethylidene diphosphate, 10-14 parts of hydrolyzed polyacrylamide, 12-17 parts of atlapulgite, 20-25 parts of sodium persulfate, 7-10 parts of sodium lignosulfonate, 5-8 parts of tannin, 12-16 parts of sodium malate, 5-8 parts of sodium sulfosuccinate, 5-8 parts of starch, 9-12 parts of methyl lactate, 0.2-0.3 part of vanadium pentoxide and 0.1-0.3 part of diisobutyl carbinol. The neutral blocking remover composition for oilfield oil extraction has the advantages of high blocking removal speed, no corrosivity due to neutrality and no dead area, can quickly dissolve the material scales, clean the oilfield stratum and remove blocking, and does not generate the phenomenon of precipitation or secondary blocking; and the cleaning waste liquid does not need to be subjected to sewage treatment after returning to the ground.

A diamine modified polylactic acid, its preparing process and its application in preparing the biodegradable medical materials, especially the tissue engineering material, are disclosed. Its advantages are excellent hydrophilicity and neutral degradation.

A mineralized porous silk protein/high-molecular material composition with high biocompatibility and biodegradability for repairing bone is prepared through preparing the aqueous solution of deglued silk protein, dropping the Ca ions contained solution in it while stirring, slowly dropping PO4 ions contained solution, regulating pH value, stirring, laying aside, centrifugal separation and washing several times, vacuum drying, grinding, and mixing with the biocompatible high-molecular material chosen from polylactic acid, copolymer of lactic acid and hydroxy acetic acid, sodium alginate, etc.

The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.